Search for a trial

Clinical Performance Study Plan (CPSP) for the use of GenDx CDx Tedopi for subject enrollment on to the OSE Immunotherapeutics Phase 3 trial (OSE2101C302) of OSE2101 versus docetaxel in HLA-A*02 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to immune checkpoint inhibitor (ARTEMIA)

This clinical performance study/clinical investigation will evaluate the safety and effectiveness of GenDx CDx Tedopi in identifying HLA-A*02 status in metastatic NSCLC subjects who may be eligible for treatment with OSE2101.

A Multicenter, Prospective, Longitudinal, Observational Study in Children and Adults with Stargardt Disease Secondary to Mutation in the ABCA4 Gene

Primary Objectives• To evaluate prognostic factors of disease progression in subjects with Stargardt disease secondary to mutation in the ABCA4 gene • To further characterize the STGD1 patient population for future interventional clinical studies